You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 10,864,159


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,864,159
Title:Method and composition for treating ocular hypertension and glaucoma
Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2.alpha. analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2.alpha. analogues in an aqueous composition.
Inventor(s): Reunamaki; Timo (Tampere, FI), Pellinen; Pertti (Lempaala, FI), Oksala; Olli (Tampere, FI), Lehmussaari; Kari (Tampere, FI)
Assignee: SANTEN PHARMACEUTICAL CO., LTD. (Osaka, JP) AGC INC. (Tokyo, JP)
Application Number:16/010,739
Patent Claims: 1. A method for treating ocular hypertension and glaucoma to a subject in need thereof, by administrating an ophthalmic aqueous solution consisting of 0.0015% w/v tafluprost as an active ingredient, 0.075% w/v polysorbate 80, 0.05% w/v disodium edetate, 2.25% w/v glycerol, 0.2% w/v sodium dihydrogen phosphate dihydrate, one or more pH adjusters, and water.

2. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1, wherein the ophthalmic aqueous solution is packaged in a single dose or unit dose container.

3. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1, wherein the ophthalmic aqueous solution is packaged in a container made of a low density polyethylene.

4. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 2, wherein the container is made of a low density polyethylene.

5. A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 4, wherein the container contains no more than 10% of any material other than polyethylene.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.